Sachs-Bloomberg Global Biotech Forum for Investing & Partnering 2004 Participant Profiles.

Business/Biotechnology Writers

BIOWIRE2K

Global Biotech Investor Forum 2004

BOSTON--(BUSINESS WIRE)--March 17, 2004

The Sachs-Bloomberg Annual Global Biotech Forum for Investing & Partnering takes place April 1-2, 2004, at the Fairmont Copley Plaza in Boston. For in-depth information about the event, visit http://www.sachsforum.com/global4_fs.html.

Below are profiles from Global Biotech Forum presenters. Breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show and conference news resource. Business Wire is the official news wire service for the Sachs-Bloomberg Global Biotech Forum for Investing & Partnering.

Company: AnorMED Inc
Ticker Symbol: AOM: TSX
Media Contact: Elisabeth Whiting
Phone: [phone]
E-mail: [e-mail]
Company URL: www.anormed.com
Press Kit URL:  http://www.anormed.com/investors/package.cfm

Product description: AnorMED's lead program on AMD3100, a stem
cell mobilizer, is in three phase II trials for stem cell transplant
in cancer patients and in preclinical studies for cardiac tissue
repair. AnorMED is also developing novel HIV entry inhibitors: AMD070,
an oral CXCR4 HIV entry inhibitor, in Phase I trials and oral CCR5
candidates in preclinical studies. The Company has licensed several
other products at various stages of clinical development to corporate
partners.

Company description: AnorMED is a biopharmaceutical company
focused on the development of small molecule therapeutics for the
treatment of a variety of diseases including cancer and HIV.

Company: atugen AG
Media Contact: Thomas Christely
Phone:[phone]
E-mail: [e-mail]
Company URL: www.atugen.com

Product description:

--siRNA therapeutic candidates in Diabetes and Oncology

--Pipeline of proprietary novel and functionally validated cancer
targets

--Largest set of KnockDown technologies (low toxic GeneBlocs
antisense molecules, stabilized synthetic siRNA)

--Superior delivery reagents transfecting almost all cell types
(transfection rate greater than 95%)

Company description: atugen AG is a technology leader in
functional gene silencing. The company is based in Berlin, Germany,
and currently has about 40 employees. atugen's in-house drug
development programs mainly focus on the generation of novel siRNA
therapeutics. Here, the company exploits its expertise in
oligonucleotide delivery and its recently discovered,
chemically-stabilized, proprietary siRNA structures. With its contract
research business , the company offers its expertise in target
validation and drug discovery to biopharmaceutical customers and
partners through research alliances and on a fee-for-service basis.

Company: Aureon Biosciences Corporation
Media Contact: Jon Edelson
Phone:   [phone]
E-mail:  [e-mail]
Company URL: www.aureon.com

Products:

--Predictive tests for cancer care examining individual response
to treatment (initially in the areas of prostate and breast cancer)

--Tissue analysis for pharmaceutical companies to enable clinical
trials and toxicology activities

Aureon's products are based on its proprietary technology platform
combining novel molecular, imaging and bio-informatic technologies.

Company Description: Aureon is applying its proprietary "systems
pathology" tissue analysis technology platform to develop predictive
clinical tests for cancer care as well as to enable bio-pharmaceutical
research and development. Systems pathology integrates clinical,
micro-anatomic, and molecular views of disease to provide new
understandings of the disease itself as well as individual response to
treatment.

Company: BIOCORTECH
Phone: [phone]
E-mail: [e-mail]
Company URL: www.biocortech.com

Product description:

--BC22 depression pre-clinical

Biocortech develops innovative pharmaceutical compounds active on
the central nervous system via two integrated proprietary platforms.

--EDIT: quantification of 5HT2C and glutamate b receptor editing
In vitro, in cellulo, ex vivo tests

--TOP: quantification of the level of expression of specific
proteins Ex vivo tests

Company description: To treat neuropsychiatric disorders,
Biocortech, localized at the Pasteur Institute (Paris) and in
Cambridge (MA), develops new classes of psychotropic drugs efficient -
on deep resistant depression by restoring deficient neural pathways -
on bipolar depression, schizophrenia and cognitive impairment by
modulating the editing mechanisms of serotonin and glutamate
receptors.

Company: CELLECTIS
Media Contact: Andre Choulika
Phone: [phone]
E-mail: [e-mail]
Company URL: www.cellectis.com
Press Kit URL:  www.cellectis.com/news

Product description: Cellectis was founded in 1999 as a spin-off
from Institut Pasteur. It is the first Company to apply the
Meganuclease Recombination System approach to in vivo genome
engineering. Cellectis is focused on the research and development of
novel Meganucleases for genome intervention and provides tools for
site directed recombination in living organisms. Cellectis is
committed to bring Genome Surgery to patients as a genuine new human
therapeutic approach.

Company description: The Company is developing Meganucleases that
can target a unique DNA break in vivo, a fundamentally enabling
technology for commercial applications as human therapeutics approach
for genetic and infections diseases, pharmaceutical discovery,
agriculture and industrial biotechnology. Cellectis' team today
consists of 34 people including 14 PhDs and the total invested capital
since the Company's inception is over USD 20 million. As of today,
Cellectis has entered into more than 24 deals on its Genome
Engineering technologies including Pharmaceutical and Global
Companies.

Company: Chronogen Inc
Media Contact: Marie-Lise Gauthier
Phone: [phone] ext 206
E-mail: [e-mail]
Company URL: www.chronogen-inc.com

Company description: Chronogen Inc., a privately-held drug
discovery company, is a leader in the identification of targets that
control the degenerative processes of aging. Based on this innovative
approach, the company is developing novel products to control lipid
and oxidative stress levels, which are established disease mechanisms
in cardiovascular disorders. The control of aging in whole model
organisms, worms and mice, has provided very valuable assets for a
drug discovery technology that will lead to novel and efficacious
drugs in significant markets including atherosclerosis, vascular
complications of diabetes, and ischemia/reperfusion injuries.
Chronogen is headquartered in Montreal, Canada.

Chronogen announced an initial closing of $17 million (CAN) in an
ongoing series B financing in November 2003. This new round of
financing closed as Chronogen continues to build its multidisciplinary
team of scientists, expands its operations, and acquires technologies
to complement its drug discovery programs.

Company: CombinatoRx, Inc.
Media Contact: Daniel Grau
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.combinatorx.com

Product description: CombinatoRx has an impressive clinical and
preclinical pipeline of novel agents, including treatments in
development for cancer and rheumatoid arthritis, and has ongoing
research in respiratory, metabolic, and infectious diseases.

Company description: CombinatoRx is creating new combination
medicines that attack disease on multiple fronts. CombinatoRx invented
the industry's first combination drug discovery platform to generate
new medicines, based upon new insights into disease networks, in a
broad range of therapeutic areas. Founded in 2000 by scientists from
Harvard and MIT, the company has raised $60M in venture capital and is
executing on its business strategy to rapidly build and commercialize
a portfolio of breakthrough products.

Company:  Concurrent Pharmaceuticals
Media Contact:  Richard Baxter
Phone: [phone]
E-mail: [e-mail]
Company URL: www.concurrentpharma.com

Product description: Concurrent has created a portfolio of
pre-clinical programs that are rapidly advancing into clinical
development in hypertension, metabolic and respiratory disease,
inflammation and Alzheimer's. In its hypertension program, Concurrent
has identified novel, highly potent, selective and orally available
renin inhibitors that tracking to plan for clinical development 2005.
The hypertension market is expected to exceed $50 Billion in the next
five years.

Company description: Concurrent Pharmaceuticals, Inc. is a drug
discovery and development company creating a portfolio of novel drug
candidates for clinically significant diseases. The company has
developed proprietary, computational drug design technology to
accelerate the discovery of advanced orally active compounds. Its lead
program is renin inhibitors for hypertension. Orally available
compounds are currently in animal studies and are expected to enter
the clinic in 2005.

Company:  ConjuGon, Inc.
Media Contact: Salvatore Braico (608-441-2890)
Investor Relations Contact: Christopher Price (703-608-3699)
Phone: [phone]
E-mail: [e-mail]
Company URL: ww.conjugon.com

Product description: ConjuGon is developing fundamentally new
biotherapeutics to treat multi-drug-resistant bacterial infections.
These biotherapeutics are based on a technology that uses harmless
bacteria to introduce engineered genes into targeted bacteria. The
genes are then expressed to form highly potent antibacterial products
which proceed to kill the target through multiple, independent
mechanisms.

Company description: ConjuGon was founded in 2001 to develop and
commercialize a novel antibacterial technology based on research done
at the University of Wisconsin-Madison. The Company, led by an
experienced team, has raised nearly $1.3 million in seed financing and
is currently raising a $3.5 million Series A round.

Company: Curis, Inc.
Ticker Symbol: CRIS
Media Contact:    Marc Charette
Investor Relations Contact:  Michael Gray
Phone:    [phone]
E-mail:  [e-mail]; [e-mail]
Company URL:  www.curis.com

Product description: Our product development approach involves
using small molecules, proteins or antibodies to modulate these
regulatory signaling pathways. We have successfully developed several
promising preclinical product candidates in the fields of kidney
disease, cancer, neurological disorders, cardiovascular disease and
hair growth regulation.

Company description: Curis is a therapeutic drug development
company principally focused on the discovery, development and future
commercialization of products that modulate key regulatory signaling
pathways controlling the repair and regeneration of human tissues and
organs. We have a broad portfolio of product candidates and a diverse
portfolio of corporate collaborations.

Company: Cyclacel Limited
Media Contact: Spiro Rombotis
Investor Relations Contact:  Paul McBarron
Phone: [phone]
E-mail: [e-mail]
Company URL: www.cyclacel.com

Company description: Cyclacel - a biopharmaceutical company that
designs and develops small molecule drugs that act on key cell cycle
regulators to stop uncontrolled cell division in cancer and other
diseases involving abnormal cell proliferation. The Company's
discovery engines integrate cell cycle biology expertise with a large
library of proprietary gene-based targets, state-of-the-art RNAi
functional genomics, chemogenomics and clinical biomarker technologies
to rapidly deliver new drugs. Nine research and development programs
are underway. Most advanced is CYC202, a Cyclin Dependent Kinase (CDK)
inhibitor, in Phase IIa trials. Corporate alliances in oncology
entered into with AstraZeneca, CV Therapeutics, Lorus, Sankyo and top
5 pharmaceutical major.

Company: Dermatrends, Inc.
Media Contact: Joanne Henry [phone]
Phone: [phone]
E-mail: [e-mail]
Company URL: www.dermatrends.com

Product description: Dermatrends(R) offers licensing and joint
development opportunities of its platform transdermal delivery
technology. The company's patented enhancer system increases
permeation to allow therapeutic delivery of many compounds not
currently available in transdermal form. Our technology platform allow
companies to extend drug patent life, while enabling transdermal
delivery of compounds not well suited to oral delivery.

Company Description: Dermatrends(R) has discovered a platform drug
delivery technology that will dramatically change the face of
transdermal drug delivery. Our in vitro tests and recent in vivo
trials have demonstrated therapeutic delivery through the skin of more
than 30 compounds. Our in vitro matrix patch tests include effective
transdermal delivery of larger molecules, exceeding 1300 AMU, an
industry breakthrough.

Company: Ecopia BioSciences Inc.
Ticker Symbol: EIA  (on TSX)
Media Contact: Karen Eugeni
Phone: [phone]
E-mail: [e-mail]
Company URL: www.ecopiabio.com

Product description: Ecopia's drug discovery platform, DECIPHER(R)
technology, has allowed us to identify compounds that have unique
chemical diversity and often define new structural classes of drugs in
the anticancer, antibacterial and antifungal markets. Of the five
compounds discovered to date, two are advancing to preclinical trials
and the Company expects to file an IND in 2005.

Company description: Ecopia has built a pipeline of new
anticancer, antibacterial and antifungal agents using its proprietary
DECIPHER(R) technology. The Company's pipeline includes two anticancer
agents, ECO-04601 and ECO-02201, an antibacterial agent, ECO-00501,
and two antifungal agents, ECO-02301 and ECO-14401. Ecopia's shares
are listed on the Toronto Stock Exchange (ticker symbol: EIA).

Company:  Eidogen, Inc.
Media Contact:  Janet Roberts ([e-mail])
Investor Relations Contact:  Ted Kingsley
Phone: [phone]
Company URL:  http://www.eidogen.com

Product description: Eidogen's is the world's first structural and
comparative proteomics enterprise software solution. TIP allows drug
discovery researchers and organizations to attack their druggability,
selectivity, toxicity, and reduced market exclusivity problems by
supporting new and truly collaborative research in target
prioritization, lead discovery, and lead optimization.

Company description: Eidogen is a Pasadena, California based
biotechnology company dedicated to delivering the finest computational
drug discovery platforms ever developed. The last decade has seen the
revolutionary human genome project transform the way our industry
identifies drug targets. In the current decade, equally important
revolutions in the fields of structural biology and computational
chemistry will transform the way our industry performs target
prioritization, lead identification, and lead optimization. Eidogen
was established to lead this revolution.

Company:          Gene Express, Inc.
Media Contact:    Brad Leone, (419-893-9600)
Investor Relations Contact: Jim Hodges, (847-234-1582)
Company Phone:    [phone]
E-mail:  [e-mail]
Company URL:      www.GeneExpressInc.com

Product description: Gene Express's revenues are generated by
providing reagent sales and high margin multi-gene expression analysis
services utilizing 700 assays at a high-throughput, Standardized
Expression Measurement (SEM) Center to researchers in the U.S., Europe
and Japan. Also, the company has developed four clinical, molecular,
diagnostic tests for lung cancer.

Company description: Gene Express, Inc. is a genomic biotech
company that sells patented, quantitative, standardized, multi-gene
expression platform technology (StaRT-PCR ) to academic institutions,
pharmaceutical and biotech companies, the Departments of Defense and
Homeland Security, and the food industry. Recently, the first project
under a two-year agreement with Pfizer, Inc. was completed.

Company:  Generex Biotechnology Corporation
Ticker Symbol:  NasdaqSC: GNBT
Investor Relations Contact:  Todd Falls
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  www.generex.com

Product description: Oralin, Generex's most advanced product in
development, is an oral insulin spray formulation for the treatment of
Type-I and Type-II diabetes. Oralin is administered directly into the
mouth as a metered-dose spray for rapid absorption by the buccal
mucosa. Oralin is currently conducting Phase IIB clinical trials in
North America.

Company description: Generex Biotechnology Corporation is engaged
in the research and development of drug delivery systems and
technology. To date, Generex has focused on developing a platform
technology for the buccal delivery of drugs that historically have
been administered only by injection. RapidMist(TM) Generex's buccal
drug delivery technology, has application to a large number of drugs.

Company: GenOdyssee SA
Media Contact: Jean-Louis Escary
Phone: + 33 1 69 29 80 55
E-mail: [e-mail]
Company URL: www.genodyssee.com

Product description: Natural variants of human therapeutic
proteins with higher therapeutic indices than reference products on
the market. The lead virology candidate, GEA007.1, is a natural
variant of human IFN-alpha that has demonstrated in vitro up to 100x
higher antiviral activity (HCV replicon model) than marketed IFN alpha
2a or 2b for hepatitis treatment. GEA007.1, in particular, has been
found with a better anti-HCV replication effect than IFN alpha 2b
against HCV genotype 1b. This sustains results obtained in vitro in
the VSV model, and in vivo with EMCV infected mice. The lead oncology
candidate is GEA009.2, another variant of human IFN-alpha, that has
demonstrated in vitro a stronger immune system stimulatory activity
with less accompanying toxicity than the current marketed IFN 2b for
cancer treatment. GEA009.2, has been found a more potent inducer of
Natural Killer (NK) cells than IFN alpha 2, which confirms results
obtained with previous ex vivo and in vivo immunological (FLC, P815,
Dendritic cells) models.

Company description: GenOdyssee (GO) is developing a series of
compounds based on exploiting genetic mutations that confer
super-therapeutic status on naturally produced therapeutic cytokines.
While many companies are searching for deleterious genes and mutations
responsible for disease pathology or susceptibility, GO, on the
contrary, is developing therapeutics based on the assumption that
natural genetic mutations derived from evolution can confer natural
superiority to the pharmacological profiles of corresponding host
human therapeutic genes, such as the genes that encode for blockbuster
therapeutic cytokines IFN-alpha and EPO.

Company:  Genstruct, Inc.
Media Contact:  John Wilbanks
Investor Relations Contact:  Keith O. Elliston
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  http://www.genstruct.com

Product description: Genstruct, Inc., the leader in biological
mechanism discovery, is developing therapeutics based on Molecular
Epistemics(TM) an unprecedented approach to systems biology that
leverages logical modeling and causal reasoning. Genstruct is building
a therapeutic product pipeline and has successfully applied its
platform to discover drug mechanisms of action and resistance.

Company description: Genstruct is uniquely positioned to leverage
the full potential of causal modeling for therapeutic discovery and
improved clinical trial design. Genstruct's position as the first
company to develop comprehensive, causal biological models is
supported by patents, technology, and techniques relating to mechanism
discovery and validated through world class collaborations.

Company: HYBRIGENICS
Media Contact: Dominique Granger
Investor Relations Contact: Eric Cohen
Phone:+ (33) 1 58 10 38 00
E-mail: [e-mail] or [e-mail]
Company URL: http:/hybrigenics.com
Press Kit URL: http:/hybrigeniccs.com/paged2_cad.htm

Company description: Hybrigenics is a leader in Drug Discovery
based on Functional Proteomics. Using innovative technology platforms,
the Company identifies, selects and validates novel disease-associated
targets in order to screen for small molecule drugs. Hybrigenics
currently runs drug discovery programs in the fields of virology and
oncology. Hybrigenics also collaborates with pharmaceutical companies
in these and other therapeutic areas for joint research and product
development.

Company: Immunitor USA Inc.
Media Contact: Dr. Aldar S. Bourinbaiar
Phone: Tel: [phone] (Thailand)
Tel: [phone] (USA)
E-mail: [e-mail]
Company URL: www.immunitor.com

Product description: Four vaccines being manufactured to prevent
or treat viral, bacterial, fungal infections; and cancer. Products are
now marketed as food supplements. The lead product is in phase III
clinical trial to be licensed as a therapeutic vaccine for AIDS
wasting. Products in pipeline include oral vaccines for smallpox,
hepatitis, and influenza.

Company description: Immunitor USA Inc., is a joint venture with
Immunitor Corporation - the first private biotech company in Thailand.
The Company has exclusive rights to technology developed by Thai
partner. This technology enables to formulate a vaccine as an oral
pill. Company's clinic and manufacturing plant are in Thailand.

Company: LifePoint, Inc.
Ticker Symbol:  AMEX: LFP
Investor Relations Contact: Linda H. Masterson
Phone: [phone]  x400
E-mail: [e-mail]
Company URL: www.LifePointInc.com

Company description: LifePoint, Inc., a leader in non-invasive
drug diagnostic technologies and solutions, has developed,
manufactures and markets the IMPACT Test System - a rapid diagnostic
testing, screening and drug monitoring device for use in law
enforcement and the workplace, and in the future, ambulances,
pharmacies, and home healthcare markets. LifePoint's patented and
proprietary technologies for the use of saliva as a non-invasive,
blood-comparable test specimen, used in conjunction with the flow
immunosensor technology licensed from the United States Navy, have
allowed LifePoint to develop a broadly applicable, rapid, on-site
diagnostic test system. The first product simultaneously detects drugs
of abuse and alcohol. The initial three target markets - law
enforcement, industrial workplace and medical emergency room - are
estimated to be over $1.6 billion in total opportunity.

Company: MacroChem Corporation
Ticker Symbol: MCHM
Media Contact: Jim Chiafery, [phone] ext. 102
Investor Relations Contact: Kim Tulimieri, 781-862-4003 ext. 357
Phone: [phone]
E-mail:    [e-mail]
Company URL:  www.macrochem.com

Product description: MacroChem is developing three drugs using its
drug-absorption enhancer, SEPA(R): Topiglan(R), a Phase 2 topical
treatment for erectile dysfunction; EcoNail(TM) a nail fungus
treatment containing econazole, and Opterone(TM) a
testosterone-deficiency cream. An Opterone dose-proportionality trial
started in late 2003. An EcoNail Phase 1-2 tolerance-efficacy trial
will commence in early 2004.

Company description: MacroChem is a specialty pharmaceutical
company that uses novel delivery systems to develop a range of
pharmaceutical products to treat important medical conditions. Its
current development portfolio contains products to treat testosterone
deficiency, fungal infections of the toenails, and erectile
dysfunction. MacroChem's core technology is modulation of skin
absorption.

Company: MethylGene Inc.
Media Contact: [e-mail]
Investor Relations Contact: [e-mail]
Phone: [phone]
E-mail: [e-mail]
Company URL: www.methylgene.com

Product description: MethylGene has a pipeline of novel targets
and inhibitors which includes MG98 for oncology in clinical trials;
MGCD010, a small molecule HDAC inhibitor for oncology with clinical
trials to be initiated this year; small molecule inhibitors of
bacterial beta-lactamases for antibiotic resistance in preclinical
development in collaboration with Merck ; and a portfolio of other
chemistry-driven research programs including HDAC inhibitors for other
non-oncology large market indications.

Company description: MethylGene is a private biopharmaceutical
company engaged in the discovery and development of novel enzyme
inhibitors for the treatment of cancer and infectious diseases. The
Company has developed expertise in rational design of isotypic
selective enzyme inhibitors and is a leader in the fields of histone
deacetylase, DNA methyltransferase , and beta-lactamase. Strong
partnerships with major pharmaceutical companies such as MGI Pharma,
Taiho and Merck help drive our programs.

Company: Munich Biotech AG
Media Contact: [e-mail]
Phone: [phone], Fax. [phone]
Company URL: www.munichbiotech.com

Product description: Munich Biotech's most advanced compound is
MBT-0206, an anti-neovascular cytotoxic agent, which is in phase II
clinical trials in various solid tumor indications. In phase I,
MBT-0206 was well tolerated and clearly showed anti-tumor activity.
Munich Biotech's second anti-cancer drug MBT-0312 has started phase I
clinical testing in Dec. 2003.

Company description: Munich Biotech AG is a privately held
pharmaceutical company. Its is developing "anti-neovascular
cytotoxics", a new class of cancer drugs with a novel cellular target,
the activated tumor endothelial cell. By destroying the blood vessels
of solid tumors these agents are potentially effective in "chocking"
of both the primary tumor and metastases.

Company: MWG Biotech AG
Ticker Symbol: NWU
Investor Relations Contact: Dagmar Metzger
Phone: [phone]
E-mail: [e-mail]
Company URL: www.THE-MWG.com

Product description: In "Genomic Information" genomes of organisms
are sequenced to identify which genes they contain. In "Genomic
Synthesis" MWG produces synthetic nucleic acids, small fragments of
DNA. The "Genomic Diagnosis" unit produces microarrays, glass slides
with up to 30,000 spots, each of which represents a gene. Microarrays
are used to identify gene function. MWG's "Genomic Technology" lab
automation unit develops and produces THEONYX robot systems for
molecular biology

Company description: MWG-BIOTECH AG Application Solutions for the
Life Sciences MWG Biotech is a provider of complete solutions around
DNA. With its four business units Genomic Information (sequencing),
Genomic Synthesis (production of synthetic nucleic acids), Genomic
Diagnosis (microarrays) and Genomic Technology (robots lab automation)
and with a strong bioinformatic backbone MWG Biotech offers its
customers complete application solutions on the exciting path from
genome to gene function.

Company:  NeuroMed Technologies Inc.
Media Contact:  Julie Jang
Phone: [phone]
E-mail:  [e-mail]
Company URL: www.neuromedtech.com

Product description: NeuroMed Technologies is the only
biotechnology company focused exclusively on calcium channels as drug
targets for the treatment of neurological diseases. NeuroMed will
commence its first clinical trial in early 2004 for its lead chronic
pain candidate, NMED-160.

Company description: NeuroMed Technologies Inc. is a private
biopharmaceutical company committed to developing the next generation
of chronic pain drugs with pipeline programs in anxiety, epilepsy and
cardiovascular diseases. The Company's drug development programs are
designed around validated clinical targets associated with large unmet
markets.

Company: Norgen Biotek Corp.
Investor Relations Contact: Yousef Haj-Ahmad
Phone: [phone]
E-mail: [e-mail]
Company URL: www.norgenbiotek.com

Product description: Based on its technology Norgen began to
manufacture bio-consumable products dealing with the genomics and the
proteomics research markets. In addition to its branded products,
Norgen offer private labeling to a number of companies. Norgen's
current focus is on the adoption of its novel technologies to the
industrial scale purification of nucleic acids and proteins and on
manufacturing/marketing its growing list of products.

Company description: Norgen is a privately owned Canadian
Biotechnology Company. It operates out of a stand-alone building
equipped with all the necessary tools. Norgen is seeking a joint
venture/financing to build a versatile cGMP facility to demonstrate
the applicability of its patented platform technologies in the
purification of nucleic acids, pharmaceutical and non-pharmaceutical
proteins as well as to market it growing list of products.

Company: Opexa Pharmaceuticals, Inc.
Public Relations Contact: Michael T. Redman
Phone:    [phone]
E-mail: [e-mail]
Web Address: www.opexapharma.com

Company description: Opexa Pharmaceuticals, Inc., founded in 2001,
is engaged in the development of therapeutics for autoimmune diseases
and graft rejection. The company's lead product, Tovaxin, is currently
being evaluated in a Phase I/II dose-escalation trial under an IND
approved by the FDA. To date, more than 130 patients have been treated
with Tovaxin. Opexa anticipates that Tovaxin will be a chronic
treatment dosed subcutaneously twice per year. The underlying
technology of Tovaxin is T cell vaccination. Tovaxin has been shown to
deplete myelin-reactive T cells, the underlying cause of MS.

Company: Predix Pharmaceuticals Holdings, Inc.
Investor Relations Contact: Christine Hayden
Phone: [phone] X1010
E-mail: [e-mail]
Company URL: www.predixpharm.com

Product description: Predix Pharmaceuticals has created a
proprietary suite of in silico technologies for the rapid discovery
and optimization of G-protein coupled receptor (GPCR) targeted drugs.
PRX-00023, a 5HT1A full agonist for treatment of ADHD, anxiety and
depression, has entered phase I clinical trials. Preclinical stage
5-HT4 partial agonist and 5-HT2B antagonists are expected to enter
clinical trials within 1 year.

Company description: Predix Pharmaceuticals is an integrated
computational - medicinal chemistry drug development company focused
on creating new drugs targeted to GPCRs. Using our proprietary GPCR
models and integrated computational-medical chemistry lead
optimization algorithms, the 32-employee company has the capacity to
discover, develop, and move 1-2 drug candidates into the clinic
annually.

Company: Serenex, Inc.
Investor Relations Contact: Ian A.W. Howes
Phone: [phone]
E-mail: [e-mail]
Company URL: www.serenex.com

Product description: Serenex has lead compounds in oncology and RA
developed from its chemo-proteomics technology. Serenex profiles
compounds across more targets in a single step than the entire
pharmaceutical industry has screened in its history and gains a level
of compound selectivity knowledge that exceeds current industry
standards by up to 100-fold.

Company description: Serenex is a drug discovery company based
near Research Triangle Park in North Carolina. The company was founded
in 2001 and has built a robust drug discovery engine, an internal
product pipeline and nine pharmaceutical collaborations around its
proprietary compound-centric chemoproteomics technology platform.

Company: Stressgen Biotechnologies Corp.
Ticker Symbol:  SSB
Media Contact: Donna Slade, 858.202.4945
Investor Relations Contact:Jennifer Matterson
Phone: [phone]
E-mail: [e-mail]
Company URL: www.stressgen.com

Product description: HspE7 is based on the covalent bonding of a
heat shock protein (Hsp), to proteins such as viral or cancer
antigens. The resulting CoValTM fusion proteins are designed to
stimulate immune responses in the disease-specific antigen present in
the fusion. CoValTM fusions use the body's immune system to combat
infectious diseases or cancer.

Company description: Stressgen Biotechnologies is focused on the
discovery, development, and commercialization of innovative,
proprietary immunotherapeutics for the treatment of infectious disease
and cancer. The Company's proprietary platform technology is based on
the covalent bonding of a stress protein, also called a heat shock
protein (Hsp), to proteins such as viral or cancer antigens.

Company: Symbollon Pharmaceuticals, Inc.
Ticker Symbol: OTCBB: SYMBA
Media Contact: Paul C. Desjourdy, 508-620-7676 x202,
[e-mail]
Investor Relations Contact: Barry Kaplan, 732-747-0702,
[e-mail]
Company URL: http://www.symbollon.com

Product description: Symbollon has completed Phase II clinical
trials evaluating IoGen(TM) as a potential treatment for cyclic breast
pain associated with fibrocystic breast disease. IoGen achieved a 50%
reduction in patient' breast pain in Phase II. Phase III trials are
planned for May 2004. Additional indications include endometriosis,
ovarian cysts and pre-menopausal breast cancer prevention.

Company description: Symbollon is a specialty pharmaceutical
company focused on developing proprietary drugs based on its molecular
iodine formulation technology. Molelcular iodine is the active species
of iodine, a proven fast acting, broad-spectrum antimicrobial and
therapeutic. Symbollon is developing product applications for its
technology in two distinct areas: women's healthcare and infection
control.

Company: Therion Biologics Corporation
Media Contact: Beth Preston, 617-761-6739
Investor Relations Contact: George Eldridge, 617-475-7212
E-mail:[e-mail]
Company URL: www.therionbio.com
Press Kit URL: http://www.therionbio.com/news.html

Product description: Therion Biologics designs off the shelf
cancer immunotherapies (cancer vaccines). This therapy is designed to
stimulate a patient's immune system to identify, attack, and eliminate
cancer cells. Earlier trials indicate that the therapy may delay or
stop disease progression and may increase overall survival.

Company description: Therion Biologics Corporation develops
therapeutic vaccines for cancer and preventive vaccines for AIDS. The
Company has two lead programs involving multiple clinical trials:
PANVAC-VF(TM) for pancreatic cancer and PROSTVAC-VF(R) for prostate
cancer. Therion is also applying its technology platform to develop
vaccines to treat melanoma, breast cancer and other solid tumors.
Therion Biologics is headquartered in Cambridge, Massachusetts.

Company: Transave, Inc.
Media Contact: Gerald Baty
Phone: [phone] ext. 31
E-mail: [e-mail]
Company URL: www.transaveinc.com

Product description: Transave's first two products are: 1) a
chemotherapeutic for lung cancer; and 2) an anti-infective for
pseudomonas infections in Cystic Fibrosis patients. These products
contain off-patent drugs that are limited in their use due to their
toxicity and dosing requirements. These are problems which Transave,
with its SLIT(TM) technology, can resolve.

Company description: Transave is focused on the development of
multiple product lines of therapeutics for lung diseases via the use
of its proprietary technology. This technology, Sustained release
Lipid Inhalation Targeting (SLIT(TM)), has wide applicability in the
development of either existing or new therapeutics for the site
specific treatment of lung diseases.

Company: Viral Therapeutics, Inc.
Investor Relations Contact: Lee Henderson
Phone: [phone]
E-mail: [e-mail]
Company URL: www.viral-therapeutics.com

Product description: Virusorb is safe and effective against all
strains of Influenza virus both in vitro and in animals. The target
market is designed for fast track status. Vagiprev is a
microbicide/spermicide/antifungal targeted to several markets with a
focus on unmet needs. Clinical trials are to begin in 2004.

Company description: VTI has developed numerous products for large
pharma and biotech companies that are in various stages of clinical
testing and in diagnostic markets. The company has proprietary
technologies to gain advantage in the market for both products and
unique development tools focused in gene/protein expression and
genomics tools and resources.

Company: Zelos Therapeutics, Inc.
Investor Relations Contact: Robert DuFresne
Phone:   [phone]
E-mail:   [e-mail]
Company URL: www.zelostherapeutics.com

Company description: Zelos Therapeutics Inc. is a product
development focused biotechnology company established in June 2000 to
develop technology from the National Research Council Canada (NRC) for
the treatment of osteoporosis, psoriasis and other diseases. Zelos has
an exclusive, worldwide license covering all fields of use for NRC
technology consisting of a unique family of small osteogenic (bone
stimulating) analogues of PTH.

Product description: Zelos' first compound is now in Phase I
clinical development and a second program is expected to enter
clinical development within the 2004 calendar year. The Phase I stage
compound, Ostabolin-CTM for injection, an analogue of the naturally
occurring Parathyroid Hormone (PTH), is under development for the
treatment of osteoporosis. PTH and PTH analogues represent the first
(and currently the only) true "bone-building" treatment for
osteoporosis. These compounds have generated extensive clinical data
over the past 30 years demonstrating the therapeutic ability in
osteoporotic patients to significantly increase bone mineral density
(BMD) and decrease fracture risk. Zelos expects that Ostabolin-CTM
will be the third PTH product to reach the market.